Medicare Enrolled
Dr. Marc Schwartz, MD
Cardiovascular Disease · Bryan, TX
Practice pattern: Clinical Cardiology— Primarily office-based clinical cardiology
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Schwartz from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Schwartz? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Schwartz
Dr. Marc Schwartz is a cardiovascular disease in Bryan, TX, with 20 years in practice. Based on federal Medicare data, Dr. Schwartz performed 15,266 Medicare services across 4,570 unique beneficiaries.
Between the years covered by Open Payments, Dr. Schwartz received a total of $10,545 from 43 pharmaceutical and/or device companies across 796 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in cardiovascular disease. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Schwartz is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice▲ Top 1% volume in TX$ $10,545 industry payments
Medicare Practice Summary
Medicare Utilization ↗15,266
Medicare services
Top 1% in TX for cardiovascular disease
4,570
Unique beneficiaries
$57
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~763 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Remote patient monitoring management, 20 min/month | 2,615 | $37 | $97 |
| Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | 2,599 | $30 | $79 |
| Principal care management services for a single high-risk disease, first 30 minutes of clinical staff time directed by health care professional, per calendar month | 2,556 | $47 | $142 |
| Remote patient monitoring device, 30 days | 1,695 | $38 | $106 |
| Office visit, established patient (30-39 min) | 1,353 | $91 | $305 |
| Electrocardiogram (EKG), 12-lead | 648 | $10 | $50 |
| Hospital follow-up visit, moderate complexity | 505 | $62 | $210 |
| Regadenoson injection (Lexiscan) for heart stress test | 481 | $43 | $244 |
| Principal care management services for a single high-risk disease, each additional 30 minutes of clinical staff time directed by health care professional, per calendar month | 480 | $36 | $94 |
| Remote monitoring of physiologic parameters, initial set-up and patient education on use of equipment | 252 | $14 | $36 |
| Echocardiogram, transthoracic | 231 | $141 | $635 |
| Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and tec | 210 | $26 | $145 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 157 | $52 | $220 |
| Evaluation of implantable heart and blood vessel monitoring system, remote up to 30 days | 129 | $18 | $83 |
| Remote pacemaker monitoring, 90 days | 118 | $22 | $100 |
| Remote pacemaker/defibrillator monitoring, 90 days | 117 | $16 | $70 |
| EKG interpretation and report | 110 | $6 | $53 |
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 106 | $1,079 | $3,800 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 106 | $626 | $798 |
| Hospital follow-up visit, high complexity | 95 | $91 | $300 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 83 | $19 | $80 |
| New patient office visit (45-59 min) | 73 | $117 | $472 |
| Initial hospital admission, moderate complexity | 66 | $92 | $400 |
| Initial hospital admission, high complexity | 66 | $126 | $605 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 50 | $5 | $26 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 50 | $75 | $101 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 48 | $332 | $1,345 |
| Ultrasound of heart with probe in esophagus, with report | 40 | $82 | $355 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 40 | $2 | $10 |
| Office visit, established patient, complex (40-54 min) | 39 | $123 | $410 |
| Ultrasound of heart, follow-up | 30 | $19 | $75 |
| Critical care, first 30-74 min | 27 | $155 | $645 |
| External shock to heart to regulate heart beat | 23 | $79 | $355 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system | 19 | $15 | $105 |
| Cardiac catheterization | 15 | $211 | $931 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 12 | $10 | $45 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 11 | $17 | $67 |
| Ultrasound of both sides of head and neck blood flow | 11 | $132 | $530 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
3.9% high complexity
5.9% medium
90.3% routine
Industry Payment Transparency
Open Payments through 2024 ↗$10,545
Total received (2018-2024)
Avg $1,506/year across 7 years
Top 30% in TX for cardiovascular disease
43
Companies
796
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$10,531 (99.9%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$14 (0.1%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$1,455
2023$1,637
2022$1,685
2021$1,950
2020$1,040
2019$1,623
2018$1,154
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Amgen Inc.
$2,236
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp)
$1,448
E.R. Squibb & Sons, L.L.C.
$888
Amarin Pharma Inc.
$730
Novartis Pharmaceuticals Corporation
$695
PFIZER INC.
$505
Janssen Pharmaceuticals, Inc
$364
Baxter Healthcare
$344
Merck Sharp & Dohme LLC
$328
ABIOMED
$287
AstraZeneca Pharmaceuticals LP
$259
SANOFI-AVENTIS U.S. LLC
$251
Abbott Laboratories
$233
Esperion Therapeutics, Inc.
$220
Kestra Medical Technology Services, Inc.
$145
Alnylam Pharmaceuticals Inc.
$143
Gilead Sciences, Inc.
$141
Regeneron Healthcare Solutions, Inc.
$127
BOSTON SCIENTIFIC CORPORATION
$123
Boston Scientific Corporation
$119
Medtronic, Inc.
$116
iRhythm Technologies, Inc.
$92
Boehringer Ingelheim Pharmaceuticals, Inc.
$91
Lexicon Pharmaceuticals, Inc.
$70
Novo Nordisk Inc
$69
Kiniksa Pharmaceuticals International, plc
$58
Amryt Pharma Holdings Ltd
$46
Medtronic Vascular, Inc.
$41
Merck Sharp & Dohme Corporation
$40
ATRICURE, INC.
$40
Kowa Pharmaceuticals America, Inc.
$37
Actelion Pharmaceuticals US, Inc.
$35
Otsuka America Pharmaceutical, Inc.
$35
Kiniksa Pharmaceuticals, Ltd.
$34
Tactile Systems Technology Inc
$31
CVRx, Inc.
$18
BIOTRONIK INC.
$18
Daiichi Sankyo Inc.
$17
Allergan Inc.
$15
CMP Pharma, Inc.
$14
CHIESI USA, INC.
$14
Avinger Inc.
$14
Bayer HealthCare Pharmaceuticals Inc.
$13
Top 3 companies account for 43.4% of total payments
Associated products mentioned in payments ›
ATRICLIP LAA EXCLUSION SYSTEM · AVEIR · Arcalyst · Assure WCD · BRILINTA · BYSTOLIC · Barostim Neo System · CAMZYOS · CHANTIX · CLEVIPREX 50MG/100ML · COBALT DR MRI SURESCAN · CONFIRM RX · CardioMEMS HF System · CaroSpir · CoreValve Evolut · Corlanor · ELIQUIS · ENTRESTO · FARXIGA · FLEXITOUCH · Flexitouch Plus · Hillrom - Cardiac Ambulatory Monitor · Hillrom - Carnation Ambulatory Monitor · INJECTAFER · Impella · Inpefa · JARDIANCE · Juxtapid · Kerendia · LEQVIO · LUX-Dx Insertable Cardiac Monitor · LifeVest · Livalo · MICRA · MULTAQ · MYCARELINK · Mitra Clip system · NEXLETOL · NEXLIZET · ONPATTRO · Ozempic · PANTHERIS · PRADAXA · PRALUENT · PRALUENT ALIROCUMAB INJECTION · Repatha · Reveal LINQ · SAMSCA · UPTRAVI · VERQUVO · Vascepa · WATCHMAN · WATCHMAN Access System · XARELTO · ZIO Patch · ZIO XT Patch
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (100%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $69 per 100 Medicare services performed
Geographic Context
Cardiovascular Diseases within 10 mi
16
Per 100K population
6.7
County median income
$58,388
Nearest hospital
CHI ST JOSEPH HEALTH REGIONAL HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Schwartz is a clinical cardiology specialist, with above-average Medicare volume (top 1% in TX), and low-engagement industry engagement, with 20 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Schwartz experienced with remote patient monitoring management, 20 min/month?
Based on Medicare claims data, Dr. Schwartz performed 2,615 remote patient monitoring management, 20 min/month services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Schwartz receive payments from pharmaceutical companies?
Yes. Dr. Schwartz received a total of $10,545 from 43 companies across 796 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Schwartz's costs compare to other cardiovascular diseases in Bryan?
Dr. Schwartz's average Medicare payment per service is $57. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Schwartz) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Cardiovascular Diseases in Bryan
Browse cardiovascular diseases in Bryan ranked by procedure volume and transparency data.
Highest volume
Top Cardiovascular Diseases in TX
Cardiovascular Diseases ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Cardiovascular Diseases in TX
Which TX cardiovascular diseases receive the most from drug and device companies.
By company
Amgen Inc. Payments to Doctors
See all physicians who received payments from Amgen Inc..
By company
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) Payments to Doctors
See all physicians who received payments from ZOLL Services LLC (A/K/A ZOLL LifeCor Corp).
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C..
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology